Skip to main content

Advertisement

SpringerLink
Log in

Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Siegal T, Bairey O (2019) Primary CNS lymphoma in the elderly: the challenge. Acta Haematol 141(3):138–145. https://doi.org/10.1159/000495284

    Article  CAS  PubMed  Google Scholar 

  2. Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM (2021) How we treat primary central nervous system lymphoma. ESMO Open 6(4):100213. https://doi.org/10.1016/j.esmoop.2021.100213

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R (2021) Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol 23(1):122–133. https://doi.org/10.1093/neuonc/noaa145

    Article  PubMed  Google Scholar 

  4. Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, Auer DP, Fuller C, Davies AJ, McKay P, Cwynarski K, British Society for H (2019) Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol 184(3):348–363. https://doi.org/10.1111/bjh.15661

    Article  PubMed  Google Scholar 

  5. Yuan XG, Huang YR, Yu T, Xu Y, Liang Y, Zhang XH, Sun CR, Zhao XY (2020) Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases. Ann Hematol 99(1):93–104. https://doi.org/10.1007/s00277-019-03821-9

    Article  PubMed  Google Scholar 

  6. Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B, European Organization for R, Treatment of Cancer Brain Tumor G (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21(14):2726–2731. https://doi.org/10.1200/JCO.2003.11.036

    Article  CAS  PubMed  Google Scholar 

  7. Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Mohle R, Low S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Hess G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Roth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G (2017) High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 31(4):846–852. https://doi.org/10.1038/leu.2016.334

    Article  CAS  PubMed  Google Scholar 

  8. Bairey O, Shargian-Alon L, Siegal T (2021) Consolidation treatment for primary central nervous system lymphoma: which modality for whom? Acta Haematol 144(4):389–402. https://doi.org/10.1159/000511208

    Article  CAS  PubMed  Google Scholar 

  9. Bairey O, Siegal T (2018) The possible role of maintenance treatment for primary central nervous system lymphoma. Blood Rev 32(5):378–386. https://doi.org/10.1016/j.blre.2018.03.003

    Article  PubMed  Google Scholar 

  10. Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G (2016) A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 127(4):411–419. https://doi.org/10.1182/blood-2015-08-664086

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the patient and clinical staff at Wakayama Medical University Hospital and Naga Municipal Hospital for their participation in this study.

Funding

This study was supported by the Japan Society for the Promotion of Science (JSPS) (KAKENHI Grant Number 21K16248 to HH).

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8509, Japan

    Tadashi Okamura, Hiroki Hosoi, Takeshi Matsufusa, Yuina Akagi, Hideki Kosako, Shogo Murata, Toshiki Mushino & Takashi Sonoki

  2. Department of Internal Medicine, Naga Municipal Hospital, Wakayama, Japan

    Yuina Akagi

  3. Department of Human Pathology, Wakayama Medical University, Wakayama, Japan

    Ryuta Iwamoto & Shin-Ichi Murata

Authors
  1. Tadashi Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroki Hosoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Matsufusa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuina Akagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryuta Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideki Kosako
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shogo Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshiki Mushino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shin-Ichi Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Sonoki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroki Hosoi.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the relevant institutional and/or national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okamura, T., Hosoi, H., Matsufusa, T. et al. Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma. Ann Hematol 101, 1379–1381 (2022). https://doi.org/10.1007/s00277-021-04744-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04744-0

Search

Navigation